Tuesday 7 May 2013

T-Cell Lymphomas - Pipeline Review, H1 2013

T-Cell Lymphomas - Pipeline Review, H1 2013


T-Cell Lymphomas Pipeline Review, H1 2013 report provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for T-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas. T-Cell Lymphomas Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
 
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 

Scope

  • A snapshot of the global therapeutic scenario for T-Cell Lymphomas.
  • A review of the T-Cell Lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the T-Cell Lymphomas pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
 

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for T-Cell Lymphomas.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding T-Cell Lymphomas pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

No comments:

Post a Comment

Note: only a member of this blog may post a comment.